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Mechanisms controlling the transition of a neural precursor cell
from proliferation to differentiation during brain development
determine the distinct anatomical features of the brain. Nitric
oxide (NO) may mediate such a transition, because it can
suppress DNA synthesis and cell proliferation. We cloned the
gene encoding the neuronal isoform of Xenopus NO synthase
(XNOS) and found that in the developing brain of Xenopus
tadpoles, a zone of XNOS-expressing cells lies adjacent to the
zone of dividing neuronal precursors. Exogenous NO, supplied
to the tadpole brain in vivo, decreased the number of prolifer-
ating cells and the total number of cells in the optic tectum.
Conversely, inhibition of NOS activity in vivo increased the
number of proliferating cells and the total number of cells in the
optic tectum. NOS inhibition yielded larger brains with grossly
perturbed organization. Our results indicate that NO is an es-
sential negative regulator of neuronal precursor proliferation
during vertebrate brain development.
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The regulation of progression from proliferation to differentiation
in the population of precursor cells has direct bearing on the
formation of a functional nervous system (Jacobson, 1991; Kan-
del et al., 2000). The signaling systems involved in regulating cell
division during brain morphogenesis are only beginning to be
understood. Accumulating evidence suggests that nitric oxide
(NO), a versatile diffusable signaling molecule (Ignarro and Mu-
rad, 1995), may contribute to controlling the transition from cell
proliferation to differentiation. NO added to cultured cells sup-
presses DNA synthesis and prevents cell proliferation (Garg and
Hassid, 1989). In several types of cultured cells, NO, endog-
enously produced in response to growth factors can act as a
permissive factor to restrict cell cycle progression and to promote
differentiation (for review, see Enikolopov et al., 1999). In Dro-
sophila, NO affects cell proliferation and differentiation in devel-
oping imaginal disks of the larvae and in the embryo (Kuzin et al.,
1996; Wingrove and O’Farrell, 1999; Kuzin et al., 2000), and in
moth, NO mediates ecdysteroid-controlled cell division in the
optic lobe (Champlin and Truman, 2000).
Several lines of evidence suggest that NO may also control
neurogenesis in the vertebrate brain. NO is produced abundantly
in developing brain by NO synthases (NOSs). The spatiotemporal
pattern of NOS expression is compatible with the possibility that
NO is an antiproliferative agent. For instance, in the developing
rodent brain, transient elevation of NOS expression correlates
with the cessation of division of committed precursor cells and
the beginning of their differentiation (Bredt and Snyder, 1994a;
Blottner et al., 1995). In the adult mouse brain, NOS-positive
neurons lie adjacent to but not within the areas of neurogenesis
(Moreno-Lopez et al., 2000). Although these observations are
consistent with the notion that NO has antiproliferative activity in
the brain, the true role that NO plays in controlling brain mor-
phogenesis remains an open question.
Xenopus laevis represents a convenient vertebrate system in
which to study the role of NO in CNS development. Division of
neural precursors, their differentiation, and synaptogenesis occur
in a spatially distinct pattern throughout development of the
tadpole (Straznicky and Gaze, 1972; Lazar, 1973). For instance,
in the optic tectum, new cells are generated in the narrow germi-
nal zone at the caudomedial border of the tectum and are dis-
placed laterally and rostrally from the germinal zone as they
differentiate and mature. Consequently, interference with the
normal course of cell proliferation would be recognized as a
disruption in the spatiotemporal pattern of development in the
midbrain.
To examine the role of NO in brain morphogenesis, we cloned
the Xenopus NOS gene (XNOS) and determined the develop-
mental pattern of its expression. We then tested the effects of
manipulating NO levels on the developing brain of the tadpole.
We report that XNOS-positive cells lie adjacent to the germinal
zone in the tectum. In addition, we found that exogenous NO
decreases, whereas suppression of NOS activity increases, the
number of proliferating cells and the total number of cells in the
brain. These reciprocal effects of the gain and loss of NO on cell
proliferation support a model in which NO acts as a negative
regulator of cell proliferation in the intact vertebrate brain.
MATERIALS AND METHODS
Animals, NOS inhibitors, and NO donors. Albino X. laevis tadpoles were
obtained by human chorionic gonadotropin-induced matings and raised
under standard conditions. At stage 45 (Nieuwkoop and Faber, 1994),
animals were anesthetized in 0.02% 3-aminobenzoic acid (Sigma, St.
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Louis, MO), and a tiny piece (10  10  30 m) of slow release Elvax
plastic polymer (DuPont, Billerica, MA) was inserted into the tectal
ventricle through an incision made in the overlying skin with a 30 gauge
needle. Elvax was prepared as described previously (Cline et al., 1987)
with stock concentrations of the NOS inhibitors 2-ethyl-2-thiopseudourea
(ETU; Sigma) and L-nitro-arginine methyl ester (L-NAME; Sigma), the
inactive enantiomer D-NAME (Sigma), or the NO donor S-nitroso-
acetylpenicillamin (SNAP; Sigma) prepared as a 1:10 ratio of chemical to
polymer matrix. Control animals were treated with Elvax impregnated
with saline (0.1 M phosphate buffer). The slow release characteristics of
Elvax have been documented for a variety of molecules in several
experimental systems (Cline et al., 1987; Cline and Constantine-Paton,
1989; Schlaggar et al., 1993; Renteria and Constantine-Paton, 1999). Low
molecular weight molecules, including L-NAME, are released at a con-
stant rate for up to 30 d (Cline et al., 1987; Renteria and Constantine-
Paton, 1999). Quantitative evaluation or bioassays of relative concentra-
tions of released chemicals demonstrated that 1% of the stock
concentration of drug is released from the Elvax polymer per day (Cline
and Constantine-Paton, 1989; Schlaggar et al., 1993). Thus, stock con-
centrations used to prepare the plastic (1 M L-NAME, 1 M D-NAME, 10
mM ETU, and 300 mM SNAP) likely reflect 10 mM L-NAME and
D-NAME, 0.1 mM ETU, and 3 mM SNAP released from the Elvax into
the brain ventricle (also see Renteria and Constantine-Paton, 1999). It is
important to note that drugs are further diluted in the CSF in the
ventricle. In separate experiments, animals exposed to even higher con-
centrations of these compounds did not display any apparent signs of
toxicity. The high specificity of the L-NAME and ETU toward NO
synthases has been extensively documented (for review, see Stamler and
Feelisch, 1996). These inhibitors each act on mammalian neuronal NOS
(nNOS), endothelial NOS, and inducible NOS with similar Ki values
(Stamler and Feelisch, 1996). We determined that80% of NOS activity
was inhibited in brain extracts prepared from animals implanted with 1 M
L-NAME Elvax but not in extracts from animals implanted with 1 M
D-NAME Elvax (also see Renteria and Constantine-Paton, 1999).
cDNA library, PCR, XNOS isolation, and sequence analysis. A short 150
bp DNA fragment was generated by PCR using Xenopus genomic DNA
and degenerative primers to the conservative portion of exon 12 of rat
neuronal NOS. This fragment was used as a probe to screen the stage 42
Xenopus tadpole cDNA library kindly provided by Dr. M. W. King
(Indiana University School of Medicine). Sequencing of cDNA clones
demonstrated that the largest open reading frame (XNOS) codes for a
protein of 1419 amino acids with 79% identity and 85% similarity to rat
neuronal NOS. Enzymatic activity of XNOS after transfection into 293
cells was determined as described previously (Stamler and Feelisch,
1996). The details of XNOS cloning and analysis will be described
elsewhere (V. Scheinker, N. Peunova, and G. Enikolopov, unpublished
procedures).
Histochemistry, antibodies, and in situ hybridization. The 1500 bp
fragment of XNOS was cloned into a pBluescript II KS vector. A
digoxigenin-UTP-labeled probe for in situ hybridization was prepared
using T3 RNA polymerase, and in situ hybridization with the whole-
mount preparations of the Xenopus tadpole brain was performed as
described previously (Hemmati-Brivanlou et al., 1990).
Immunocytochemistry with whole-mount preparations and sections of
the tadpole was performed as described previously (Harlow and Lane,
1990). Monoclonal antibodies to neuron-specific type-II -tubulin (N-
tubulin), N-CAM (developed by U. Rutishauser, Memorial Sloan-
Kettering Cancer Center, New York, NY), and Islet-1 (developed by T.
M. Jessell, Columbia University, New York, NY) were obtained from the
Developmental Studies Hybridoma Bank developed under the auspices
of the National Institute of Child Health and Human Development and
maintained by The University of Iowa Department of Biological Sciences
(Iowa City, IA). An anti-mouse antibody conjugated to fluorescein
(Roche Molecular Biochemicals, Indianapolis, IN) was used as a second-
ary antibody. Specimens were visualized and photographed under fluo-
rescence or Nomarski optics on a Zeiss (Thornwood, NY) Axiophot
fluorescent microscope. Antibodies to XNOS were R20 polyclonal anti-
bodies to rat neuronal NOS (Santa Cruz Biotechnology, Santa Cruz, CA).
These antibodies were raised against a 20-amino acid (aa)-long nNOS-
specific peptide, which is identical in rat nNOS (position 1400–1419) and
Xenopus XNOS (position 1390–1409). They recognized a specific band
in extracts from the rat and Xenopus brains and cloned rat nNOS and
XNOS cDNA expressed in cultured cells and analyzed by Western
blotting.
For nuclei visualization, brain sections were stained with 4,6-
diamidino-2-phenylindole (DAPI), a fluorescent DNA stain (Molecular
Probes, Eugene, OR), at 1 M. To identify cells in S phase, tadpoles were
injected with 50 g/ml 5-bromo-deoxyuridine (BrdU; Becton Dickinson,
Mountain View, CA). After 2 hr of survival, animals were fixed in 3.7%
paraformaldehyde for 2 hr and then in 70% ethanol overnight. BrdU-
labeled S phase nuclei were visualized after denaturating DNA in 2N
HCl and 0.5% Triton X-100 for 2 hr and incubation with fluorescein-
conjugated antibodies to BrdU (Becton Dickinson), as suggested by the
manufacturer. Analysis of apoptosis during tadpole brain development
was performed on 20 m brain sections by terminal deoxynucleotidyl
transferase-mediated biotinylated UTP nick end-labeling (TUNEL) as-
say (Roche Molecular Biochemicals) as suggested by the manufacturer.
Samples were analyzed on a Zeiss Axiophot fluorescent microscope and
a Noran Instruments (Middleton, WI) confocal microscope.
Cell count and volume measurement. Horizontal 20 m sections of the
control and treated animals were collected for cell counting. Each group
contained three to five animals. Three sequential matching dorsal 20 m
sections, representing most of optic tectum, of each animal were collected
and used to determine the volume, cell number, cell density, and number
of BrdU- and TUNEL-positive cells. Thus, each number presented for
the comparison in Tables 1–3 is a result of the measurements conducted
on 9–15 sections, which minimized the possible error associated with the
variability in brain sectioning between animals.
To determine the surface of the cell body area, borders of the cell body
region of the midbrain were drawn over the projection of each section of
the series at a magnification of 10, and the surface area was determined
by superimposing a point-counting grid. The thickness of the section was
determined by Z-micrometer after staining. The volume of the section
was calculated by multiplying the area by the thickness. The total number
of cells was determined using the optical disector method (Coggeshall,
1992). In each section of the series, the total number of DAPI-stained
nuclei were counted within 40  40  5 m sampling boxes selected
randomly throughout the area. Cells that were intersected by the sam-
pling frame and cells in the lower-most focal plane were excluded from
counting. Average counts calculated from sampling boxes were extrapo-
lated for the entire volume of the cell body area of the section. The
number of BrdU- and TUNEL-labeled cells was determined throughout
the entire section. To avoid oversampling and undersampling because of
the size and shape difference, the size of DAPI stained nuclei in the
midbrain area was determined for both coronal and horizontal sections
of animals exposed to Elvax with L-NAME, D-NAME, ETU, or saline.
No statistically significant differences in the area size of the nuclei were
found between the sections in all of the pairwise comparisons (in all
cases p 0.2); thus, no stereological corrections for sampling errors were
applied. Data for three sections were combined to represent the volume
and the cell number of each brain.
RESULTS
Cloning and distribution of NOS in Xenopus
We cloned NOS cDNA from a Xenopus tadpole stage 42 cDNA
library using highly conserved regions from mammalian and Dro-
sophila NOS genes as probes. The nucleotide and deduced amino
acid sequences of the cloned XNOS gene show the highest simi-
larity to the neuronal isoform of NOS (nNOS or NOS1) of mam-
mals (Fig. 1a). The deduced XNOS protein contains the determi-
nants that are crucial for NOS activity, including regions for
binding flavin mononucleotide, flavin-adenine dinucleotide,
NADPH, tetrahydrobiopterin (BH4), heme, and calmodulin and a
consensus site for phosphorylation by cAMP-dependent PKA
(Bredt and Snyder, 1994b; Nathan and Xie, 1994; Wang and
Marsden, 1995). The N terminus of XNOS contains a PDZ motif,
which is crucial for association with PDZ domains of other pro-
teins, such as PSD-95, 1-synthrophin (Brenman et al., 1995), and
CAPON (Jaffrey et al., 1998). When expressed in cultured cells,
XNOS cDNA produced a polypeptide of the expected size of 160
kDa, similar to mammalian neuronal NOS and NOS from the frog
brain (Fig. 1b). XNOS generated NO with high efficiency after
transfection into cultured cells (Fig. 1c). Production of NO was
dependent on the presence of calcium, BH4, and NADPH, and was
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completely blocked by application of the specific inhibitors of NOS
L-NAME and ETU.
In situ hybridization using the XNOS probe shows that
XNOS RNA is present in cell bodies located in a distinct
pattern in the optic tectum, telencephalon, hindbrain, and
retina of the tadpole (Fig. 1d). A similar pattern is seen after
histochemical NADPH-diaphorase staining for NOS activity
(Fig. 1e), suggesting that XNOS-positive cells account for the
majority of the diaphorase-positive cells in the optic tectum.
Together, the gene structure, enzymatic properties, and distri-
bution of XNOS indicate that we have cloned the ortholog of
the mammalian neuronal isoform of NOS.
Differentiation of tadpole brain tissue is accompanied by the
continuous generation of new neurons in a narrow germinal zone
at the caudomedial edge of the optic tectum (Straznicky and
Gaze, 1972). If NO triggers the transition from proliferation to
differentiation, one might expect a source of NO to be adjacent to
the germinal zone of the tectum where cells undergo this transi-
tion. To determine the relative positions of proliferating cells and
NOS-expressing cells in animals from stages 43–50, cells in S
phase were labeled with BrdU, and NOS-positive cells were
identified by in situ hybridization with XNOS RNA. BrdU-
positive cells occupy a narrow crescent-shaped proliferative zone
in the caudal and caudomedial regions of the optic tectum at all
stages examined (Fig. 2a,d). A narrow band of XNOS-positive
cells was found to lie adjacent to the proliferative zone of the
optic tectum (Fig. 2b,e). As in the optic tectum, XNOS-positive
cells in the telencephalon and hindbrain lie adjacent to prolifer-
ative zones. Sagittal views of the brains reveal two clusters of
XNOS-positive cells in the midbrain, one located dorsally in the
optic tectum, and a second located ventrally in the floor of the
midbrain (Fig. 2c,f). The dorsal cluster of XNOS-positive cells
lies adjacent to the optic tectum proliferative zone. The juxtapo-
sition of the BrdU- and the XNOS-positive cells is most clearly
seen in Figure 2g–k, which are double-labeled for XNOS and
BrdU. It is interesting to note that the XNOS- and BrdU-positive
cells remain adjacent throughout this developmental period up to
stage 50, the latest stage examined, despite the continuous cell
proliferation and increase in brain size during this time. This
suggests that XNOS expression in these cells adjacent to the
Figure 1. Structure and expression of
XNOS. a, Structure of XNOS cDNA.
cDNA (6.5 kb) was cloned from a stage
42 Xenopus cDNA library. It corre-
sponds to a protein of 1419 aa, which
has all of the regions of neuronal NOS
isoforms conserved between mammals
and Drosophila. FAD, Flavin-adenine
dinucleotide; FMN, flavin mononucle-
otide. b, Expression of XNOS. Western
blots of protein extracts were probed
using a rat nNOS- and XNOS-specific
polyclonal antibody. Each lane was
loaded with 25 g of protein isolated
from 293 cells transfected with rat
nNOS cDNA ( first lane), 293 cells
transfected with XNOS cDNA (second
lane), and adult Xenopus frog brain
(third lane). The blot was treated with
R20 polyclonal antibody raised against a
20 aa peptide, which is identical in both
rat nNOS (positions 1400–1419) and
Xenopus XNOS (positions 1390–1409).
c, Enzymatic activity of recombinant
XNOS. 293 cells were transfected with
XNOS cDNA, and the NOS activity in
the cell extract was measured using the
arginine-to-citrulline conversion assay
in the presence or absence of various
cofactors and inhibitors. d, In situ hy-
bridization of XNOS RNA probe in
whole-mount stage 47 tadpole brain and
eyes. ret, Retina; telen, telencephalon;
tectum, optic tectum; mb, midbrain; hb,
hindbrain; R, rostral; C, caudal. e,
Whole-mount NADPH-diaphorase
staining of the tadpole brain at stage 46.
The region depicted corresponds to the
central lef t portion of d. Light staining
illustrates NADPH-diaphorase-positive
cell bodies in the caudal optic tectum.
Note that their position is similar to that
of XNOS-positive cells in d. The cluster
at the bottom corresponds to the
XNOS-positive cells of the hindbrain in
d. The dotted line marks the optic tec-
tum; M, midline. Scale bars: d, 100 m;
e, 25 m.
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proliferative zone is likely to be transient. The critical observation
from these experiments is that although the germinal zone itself
is free of NOS, it is closely apposed to cell bodies of NOS-
expressing cells. This distribution may reflect a functional role of
NO as a signal to these newly dividing cells.
NO donors decrease cell proliferation
To test the effect of exogenously supplying NO to the developing
tadpole brain, we inserted into the brain ventricle of stage 45
tadpoles pieces of the slow release matrix Elvax impregnated with
SNAP, a widely used donor of NO, which releases NO during
hydrolysis. Control animals were implanted with Elvax prepared
with saline. One and 3 d later, animals were injected with BrdU
for 2 hr, followed by fixation. Horizontal sections of the midbrain
containing the optic tectum were analyzed for the following
parameters: the total number of cells (as measured by the number
of DAPI-stained nuclei), the number of proliferating cells (as
measured by BrdU incorporation), the number of apoptotic cells
(as measured by TUNEL assay), the relative numbers of BrdU-
and TUNEL-positive cells per 103 total cells (BrdU and TUNEL
indices), the volume, and the cell density (Fig. 3, Table 1).
Exogenously supplied NO drastically decreases the number of
proliferating cells and the BrdU index in the midbrain at day 1 to
5% of the control values (Fig. 3, Table 1). By 3 d, the effect of
SNAP on cell proliferation in the midbrain was not significantly
different from controls, likely reflecting the extensive hydrolysis
of the NO donor and decreased NO release from the Elvax. It is
important to note that the resumption of normal rates of cell
Figure 2. Complementary patterns of
NOS expression and BrdU incorporation
in the developing Xenopus brain. Whole-
mount brains from stage 43 (a–c, g) and
47 (d–f, h) tadpoles are shown labeled for
BrdU (a, d, g, h) after 2 hr of survival and
by in situ hybridization for XNOS (b, c,
e–h). Dorsal views of brains (a, b, d, e)
from different animals are aligned to
show the relative position of BrdU- and
XNOS-positive cells in brains of compa-
rable stages. XNOS-positive cells are lo-
cated in the telencephalon, midbrain, and
hindbrain, neighboring but not overlap-
ping sites of BrdU incorporation. Sagittal
views of whole-mount brains (c, f ) show
the dorsoventral distribution of XNOS-
positive cells. Two clusters of XNOS-
positive cells are located in the caudal
midbrain. One cluster lies in the caudal
optic tectum on the roof of the midbrain
near the tectal proliferative zone, and a
second cluster is in the ventral midbrain.
Whole-mount preparations, viewed sagi-
tally ( g, h), and horizontal sections (i–k)
of the optic tectum were double-labeled
for BrdU and XNOS expression by in situ
hybridization. The dorsal cluster of
XNOS-positive cells in the optic tectum
( g–k, black arrows) lies adjacent to
BrdU-positive cells in the proliferative
zone ( g–k, white arrows) at stages 43 and
47. The optic tectum is located on the
dorsal aspect of the caudal midbrain, as
shown in c and f. telen, Telencephalon;
mb, midbrain; hb, hindbrain; R, rostral; C,
caudal; D, dorsal; V, ventral. In i–k, ros-
tral is at the top. Scale bar, 50 m.
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proliferation by the 3 d time point indicates that the effect of
SNAP on cell proliferation is reversible and that the concentra-
tion of SNAP used in these experiments was not toxic. This is
corroborated by the results of the TUNEL assay (see below). The
cell density, cell number, and midbrain volume were significantly
reduced after 3 d of SNAP treatment (Fig. 3, Table 1). Although
an increase in programmed cell death in response to NO could, in
principle, contribute to these effects, including both the decrease
in the total number of cells in the midbrain and the decrease in
midbrain volume, we observed no significant change in the rela-
tive number of TUNEL-positive cells (TUNEL index) in SNAP-
treated brains.
NOS inhibitors distort brain morphogenesis
The close proximity of proliferating and NOS-expressing cells in
the optic tectum and data from the NO donor experiments above
Figure 3. Increased levels of NO decrease
cell proliferation in the developing brain.
Animals were treated for 1 or 3 d with
saline solution (Control ) or NO donor
SNAP. Sequential horizontal brain sections
were stained with DAPI to stain nuclei (a–
d), with BrdU antibodies to label prolifer-
ating cells (e–h), and with TUNEL to label
apoptotic cells (i–l ). Rostral (R) is at the
top; C, caudal. The brain regions telenceph-
alon (telen), midbrain, and optic tectum are
marked on the lef t; marking applies to all
images. One day of exposure to the NO
donor SNAP decreases BrdU incorporation
in proliferative zones throughout the brain
without causing any apparent change in ap-
optosis. By 3 d, BrdU incorporation into
experimental and control brains appears
comparable likely because of hydrolysis of
SNAP. The histograms on the right depict
quantitative changes induced by SNAP,
which are presented in more detail in Table
1. **p  0.01. Scale bar, 50 m.
Table 1. NO donor SNAP decreases cell number, brain volume, and cell density in the tadpole brain
Control, 1 d SNAP, 1 d
Change
(% of control) Control, 3 d SNAP, 3 d
Change
(% of control)
Cell number 5020 82 3983  606 79.3 9125  194 5012 594** 54.9
Brain volume (mm3  104) 78.4  4.8 66.2  6.4 84.4 116.5  6.2 80.1  8.6* 68.8
Cell density (cells/mm3  104) 64  5 60  14 93.8 78  3 63 2 80.1
BrdU-positive cells (total) 310 83 12  1** 3.9 473  7 315 6** 66.6
BrdU-positive cells/103 cells
(BrdU index) 62 4 3  0.5** 4.8 52  5 63 6** 121.0
TUNEL-positive cells (total) 190 3.5 132  10** 69.4 163  15 80 10** 49.1
TUNEL-positive cells/103 cells
(TUNEL index) 38 2 34  3 89.4 18  2 16 1 88.9
Tadpole brains were implanted with pieces of Elvax impregnated with NO donor SNAP or saline solution as a control. Each group contained three to five animals.
Identification of the optic tectum was based on unique anatomical landmarks. Depending on the age of the tadpoles, it takes three to five 20 m horizontal sections to
encompass the entire tectum. The number of sections encompassing the optic tectum did not change significantly in the control and SNAP-treated animals (4  1, p 	 0.2
on day 1; 4  1, p 	 0.1 on day 3). Three sequential matching sections from control and experimental animals containing the optic tectum were used to determine the volume
and the cell number in the midbrain (for more details, see Materials and Methods). Differences of means of the measured parameters were analyzed by ANOVA (p and F
values for the significant changes are given below). All data are mean  SE *p  0.05; **p  0.01. One day of exposure to SNAP caused inhibition of cell proliferation in
the treated Xenopus brain, as revealed by a significant decrease of total number of BrdU-positive cells to 3.9% of control levels (p  0.01; F 	 26) and of the BrdU index to
4.8% of control (p 0.01; F	 224.4). The cessation of cell proliferation was transient, and 3 d after implantation, the BrdU index in the treated brain did not differ significantly
from the control, indicating the restoration of proliferative potential of ventricular cells. After 3 d of the experiment, the cell number in treated Xenopus brain was significantly
decreased to 54.9% of control levels (p 0.01; F	 43.3) and was accompanied by significant decrease of brain volume to 68.8% of control (p 0.05; F	 11.7) and cell density
to 80.1% (p  0.01; F 	 21.9). The decrease and restoration of cell proliferation caused by the NO donor were not accompanied by significant changes in programmed cell
death as determined by TUNEL index.
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are consistent with the proposed antiproliferative role of NO
during Xenopus brain development. To test the causative role of
NO in cell cycle arrest of neuronal precursors and to determine
whether production of NO is necessary for cell cycle arrest and
subsequent differentiation of neuronal precursors in the develop-
ing Xenopus brain, we inhibited NOS activity in the brain by using
Elvax matrix impregnated with an NOS inhibitor, either
L-NAME or ETU, or with saline as a control. Pieces of impreg-
nated matrix were inserted into the brain ventricle of stage 45
tadpoles. After 3 and 7 d of treatment, the brains were examined
for changes in the patterns of cell division and differentiation, cell
number, and overall size and morphology.
Both L-NAME and ETU significantly increased the total and
the relative numbers of proliferating cells (BrdU index) in the
brains of experimental animals in comparison with the brains of
control animals. This was observed both at 3 and 7 d after the
onset of drug treatment (Fig. 4, Table 2). Figure 4 shows two
examples each of control and L-NAME-treated brains photo-
graphed as whole-mount preparations by traditional fluorescence
microscopy and by confocal microscopy. In both examples, the
numbers and distributions of BrdU-labeled cells are increased in
L-NAME-treated animals. In contrast to the distribution of
BrdU-positive cells in control brains, which is confined to a
narrow band of cells within the proliferative zone in the caudo-
medial tectum, BrdU-labeled cells in L-NAME-treated animals
were distributed throughout the optic tectal lobe. This is most
clearly seen in projections of confocal images collected through
the dorsal optic tectum (Fig. 4c,d), which show a wide area of
BrdU-positive cells in L-NAME-treated animals extending ros-
trally and laterally in the tectum, in the normally cell-sparse
neuropil region. L-NAME increased the relative number of
BrdU-positive cells (BrdU index) to 262% of the control level at
3 d after treatment (Table 2). This increase was maintained at
182% of the control values at 7 d of treatment. Similarly, ETU, a
structurally different inhibitor of NOS, increased the BrdU index
to 247% of the control value at 7 d of treatment.
To assess whether the surplus of dividing cells in animals
treated with NOS inhibitors increased the number of cells in the
midbrain, we stained sections with DAPI to reveal the cell nuclei.
In control brains, cells in the optic tectum occupy a crescent
extending along the medial and caudal edges of the tectal lobe
(Fig. 5a). Only a few scattered cell bodies are located within the
neuropil region, where input axons mingle with tectal cell den-
drites. Midbrains of animals treated with NOS inhibitors have
significantly more DAPI-stained cells than midbrains of control
animals (Figs. 5b–d, 6a,b; Table 2). L-NAME-treated brains have
more cells than controls at 3 and 7 d (141 and 164% of the control
values, respectively), and ETU-treated brains have 154% of the
control cell value at 7 d of treatment. These data suggest that the
surplus cells in the S phase successfully completed the cell cycle
by division and contributed to an increase in cell number in the
brain. Extra cells distorted the lamination pattern in the optic
tectum, formed ectopic islands, and filled the tectal neuropil.
A decrease in programmed cell death may contribute to the
increase in cell numbers after treatment with NOS inhibitors. We
assayed the number of apoptotic cells with the TUNEL assay to
test the effect of inhibition of NOS on programmed cell death in
the developing tadpole brain. Figure 6 shows adjacent sections of
the optic tectum of animals treated for 3 d with Elvax impreg-
nated with saline solution or with the NOS inhibitor L-NAME
stained with DAPI to reveal the total number and distribution of
cells (top row) labeled with BrdU to reveal proliferating cells
(middle row) and assayed by TUNEL to reveal apoptotic cells
(bottom row). Although the BrdU index and the total number of
DAPI-stained nuclei significantly increased after a 3 d exposure
to L-NAME, there was no corresponding change in the relative
number (TUNEL index) or distribution of TUNEL-positive ap-
optotic cells (Fig. 6, Table 2). This demonstrates that pro-
grammed cell death did not significantly contribute to the in-
crease in the total cell number after NOS inhibition.
To test whether the increased number of cells affects the size of
the tadpole brain, we determined the volume of the dorsal mid-
brain and the cell density in control brains and in brains after
inhibition of NOS (Table 2). Both L-NAME and ETU signifi-
cantly increased cell density in the midbrain after 7 d of treatment
to 152 and 125% of the control values, respectively. Treatment
with ETU for 7 d also resulted in a significant increase of the
midbrain volume (124% of the control value; Table 2).
We conducted an additional series of experiments designed to
test the effect of D-NAME, the biologically inactive enantiomer of
L-NAME, on cell proliferation in the tectum. Table 3 shows
pairwise comparisons of the major parameters of cell prolifera-
tion and cell density after exposure to saline versus D-NAME,
L-NAME versus saline or D-NAME, and ETU versus saline or
D-NAME. These results show that although there were no statis-
tically significant differences between changes evoked by saline
and D-NAME, there were highly significant differences between
the action of both L-NAME and ETU compared with either
saline or D-NAME. The results presented in Table 3 are in very
good agreement with the results presented in Table 2 and Figures
4–6, and both confirm and extend the conclusions about the
specificity of the effect of NOS inhibition on cell proliferation in
the developing tadpole brain.
Figure 4. NOS inhibitors increase cell proliferation in the optic tectum.
Animals were treated with Elvax impregnated with the NOS inhibitor
L-NAME or saline as a control. Three days later, dividing cells were
labeled by BrdU incorporation for 2 hr. The distribution of BrdU-labeled
cells is shown for two pairs of animals as whole-mount images of the optic
tectum photographed by fluorescent microscopy (a, b) or as a projection
of confocal optical sections through the tectum (c, d). L-NAME increases
the number of cells labeled by BrdU incorporation and causes an expan-
sion of BrdU-labeled cells outside on the normal proliferative zone.
Dotted lines mark the midbrain. Rostral (R) is at the top; C, caudal. Scale
bar, 50 m.
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Effect of NOS inhibitor on neuronal differentiation
To determine whether the excess cells generated as a result of
NOS inhibition are able to differentiate and express neuronal
markers, we labeled brain sections with the pan-neuronal markers
N-tubulin and N-CAM (Fig. 7a–d). In both control and L-NAME-
treated brains, N-tubulin and N-CAM immunoreactivity labeled
differentiated tectal cell bodies and was concentrated in the tectal
neuropil, consistent with their distribution in neuronal processes.
Importantly, the staining patterns suggest that surplus cells in
L-NAME-treated brains differentiate and express neuronal anti-
gens. Both N-tubulin and N-CAM staining patterns also demon-
strate the distortion of brain morphogenesis and tectal cell lam-
ination, shown by DAPI staining in Figure 5. The cell body region
of the treated brains appears thicker. In addition, the greatly
disorganized neuropil was more loosely and chaotically packed
with processes, and the border between the neuropil and the cell
body region was markedly irregular.
Antibodies to Islet-1 stain a subset of ventral motoneurons in
chick, which are committed very early during vertebrate brain
development (Ericson et al., 1992). Coronal brain sections
through the rostrocaudal extent of the brain indicate that NOS
inhibition did not affect the number or distribution of Islet-1-
expressing cells, although the increase in the size of the brain
attributable to exposure to the NOS inhibitor was apparent (Fig.
7e,f). This is consistent with the early differentiation of these
neurons occurring before the inhibitors were applied at stage 45.
These data provide added support that the effects of NOS inhib-
itors on cell proliferation are specific. In addition, they suggest
that NOS inhibition can influence the development of cells in the
brain within a specific window of their development as they exit
the cell cycle and begin to differentiate.
DISCUSSION
The Xenopus brain grows throughout larval development in a
consistent pattern: new precursor cells are produced in discrete
germinal zones of the brain; they stop dividing and are displaced
laterally and rostrally from the germinal zone; and the cells
differentiate and establish functional connections with other cells.
Studies of mouse, chick, and frog development have revealed a
Table 2. NOS inhibitors increase cell number, brain volume, and cell density in the tadpole brain
Control, 3 d L-NAME, 3 d
Change
(% of control) Control, 7 d L-NAME, 7 d
Change
(% of control) ETU, 7 d
Change
(% of control)
Cell number 3644  158 5136  339* 140.9 8373 928 13742  510* 164.1 12870 690* 153.7
Volume (mm3  104) 52.7  3.8 67.8  9.1 128.7 99.4 4.9 107.0  3.7 107.6 123.0 4.3* 123.7
Cell density
(cells/mm3  104) 69  7 76  11 110.1 84  6 128  10* 152.4 105 3* 125.0
BrdU-positive cells
(total) 133  13 499  40** 375.2 141 10 424  40* 300.7 537 25* 380.9
BrdU-positive cells/103
cells (BrdU index) 37  3 97  5** 262.1 17  2 31  3* 182.4 42  3* 247.1
TUNEL-positive cells
(total) 115  7 168  16** 146.1 83 8 123  12* 148.2 179 25* 215.7
TUNEL-positive
cells/103 cells
(TUNEL index) 32 3 33  4 103.1 10  1 9  1 90.0 14  4 140.0
Tadpole brains were implanted with pieces of Elvax impregnated with NOS inhibitors L-NAME and ETU or saline solution as a control. Data were collected as described
in Table 1. The number of sections encompassing the optic tectum did not differ significantly between control and treated animals after 3 d (4  1 in all groups; p 	 0.2) or
7 d (5  1 in all groups; p 	 0.3) of treatment. Changes after 3 d of treatment with L-NAME or saline were analyzed as described in Table 1 (*p  0.05; **p  0.01). Data
collected after 7 d of treatment with L-NAME, ETU, or saline were subjected to one-way ANOVA with treatment (F(2,6) 	 15.58; p	 0.004) as the main effect. Two pair-wise
subsequent planned comparisons were adjusted for experiment-wise error rate ( 	 0.05) by using a critical value of  	 0.025. For this experiment, *p  0.025. Inhibition
of NOS during Xenopus brain development resulted in multiple changes. Proliferation as measured by BrdU index was significantly increased. After 3 d of treatment, the BrdU
index of the brain treated with L-NAME was 262.1% larger (p  0.01; F 	 107) than in the control animals. It remained higher after 7 d of treatment with both inhibitors:
182.4% of control after treatment with L-NAME (p  0.025; F 	 5.0) and 247.1% after treatment with ETU (p  0.01; F 	 15). Total cell number in the treated brain was
also significantly increased: to 140.9% of control (p  0.05; F 	 15.9) after 3 d of treatment with L-NAME, to 164.1% of control (p  0.01; F 	 27) after 7 d of treatment
with L-NAME, and to 153.7% of control (p  0.01; F 	 18.9) after 7 d of treatment with ETU. Volume was significantly increased after 7 d of treatment with ETU to 123.7%
of control (p  0.025; F 	 7). Cell density significantly increased after 7 d of treatment with L-NAME to 152.4% of control (p  0.01; F 	 19.5) or with ETU to 125% of
control (p  0.025; F 	 4). Changes in cell number were not accompanied by significant changes in the rate of programmed cell death as measured by TUNEL index.
Figure 5. Inhibition of NOS increases cell number and distorts lamination
in the developing brain. Compared with brains of control animals treated
with saline (a), DAPI staining of horizontal sections through the optic
tectum reveals a larger number of nuclei in the cell body layer and disrup-
tion of the cellular distribution in the brains of animals treated with ETU
(b) or L-NAME (c, d). In some cases, such as the example shown in b,
clusters of extra cells formed ectopic islands (arrowhead) within the tectal
neuropil, which normally contains densely packed processes. In the major-
ity of cases, ectopic cells occupied the lateral tectum and filled the tectal
neuropil (c, d). Tectal neuropil (np) and cell body layer are labeled in the
control image (a). Rostral (R) is at the top; C, caudal. Scale bar, 50 m.
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number of growth and transcription factors that determine the
patterning of the developing vertebrate brain; however, the mech-
anisms that determine how precursor cells coordinately cease
proliferating and differentiate are still unknown.
Here we show that NOS activity regulates cell number in the
developing brain of the tadpole. NOS inhibition results in excess
cell division, an increase in the total number of cells in the
developing brain, an increase in the size of the brain, and a
profound distortion of the overall cellular organization of the
brain. Conversely, increased levels of NO have a reciprocal effect:
reduced cell division, a decrease in the total number of cells, and
a decreased brain size. The observed changes in cell number can
be attributed to changed proliferation. Together, these data indi-
cate that NO acts as an essential antiproliferative factor.
In addition, our results demonstrate that the pool of precursor
cells capable of differentiating into mature cells of the optic
tectum can undergo additional cycles of division in the absence of
NO, thus suggesting that their capacity to continue dividing is not
predetermined.
In the optic tectum of Xenopus, NO may act downstream of
growth factors such as NGF and BDNF to regulate cell prolifer-
ation during development of the visual system (Cohen-Cory and
Fraser, 1994), because considerable evidence indicates that many
of the pleiotropic effects of growth factors are mediated through
NO (Peunova and Enikolopov, 1995; Hikiji et al., 1997; K. H. Lee
et al., 1997; Obregon et al., 1997; Papapetroupoulos et al.,
1997a,b; Poluha et al., 1997; Babaei et al., 1998; Cote et al., 1998;
Kim et al., 1998; Nisoli et al., 1998; Phung et al., 1999; Nakagawa
Figure 6. NOS inhibition does not in-
crease apoptosis. Animals treated for 3 d
with saline solution (a, c, e) or the NOS
inhibitor L-NAME (b, d, f ) were injected
with BrdU. Two hours later, the animals
were killed, and alternating horizontal
brain sections were stained with DAPI to
stain nuclei (a, b), with BrdU antibodies to
label proliferating cells (c, d), and with
TUNEL to label apoptotic cells (e, f ). Al-
though inhibition of NOS activity signifi-
cantly increased the number of BrdU-
incorporating cells and the total number of
cells in the midbrain, TUNEL-positive
cells were not changed. Note that single
horizontal sections only show a fraction of
the BrdU-positive cells seen in whole-
mount sections (Fig. 4). The histograms on
the right depict quantitative changes in-
duced by NOS inhibitors, which are pre-
sented in more detail in Table 2. np, Neu-
ropil; R, rostral; C, caudal. *p 0.05; **p
0.01. Scale bar, 50 m.




(% of PBS) L-NAME
Change,
L-NAME
(% of D-NAME) ETU
Change, ETU
(% of D-NAME)
Cell number 7138  490 7742 584 109 10396 806 134* 8639 279 112
Brain volume (mm3  104) 107  3 102  6 95 115.5  9 113 91  4 99
Cell density (cells/mm3  104) 66.7  5 76 3 114 90  9 118 95  2 125*
BrdU-positive cells (total) 152 36 133 16 88 441  26 332* 334 10 251*
BrdU-positive cells/103 cells
(BrdU index) 21 3 17  1 81 42  3 247* 39  3 229*
Tadpole brains were implanted with pieces of Elvax impregnated with NOS inhibitors L-NAME or ETU, inactive enantiomer D-NAME, or saline solution. Each group
contained three animals. After 3 d of treatment, data were collected and analyzed as described in Table 2. Data were subjected to one-way ANOVA with treatment (F(3,9) 	
5.48; p 	 0.02) as the main effect. Three subsequent pair-wise planned comparisons were adjusted for experiment-wise error rate ( 	 0.05) by using a critical value of
 	 0.017. For this experiment, *p  0.017. Inhibition of NOS by either L-NAME or ETU compared with either D-NAME or saline resulted in multiple changes in the
developing tadpole brain, as determined by sampling by three matching sections. The BrdU index of the brain treated with L-NAME was 247% larger (p  0.017; F 	 40)
than in the control D-NAME-treated animals. It was also larger in ETU-treated animals: 229% of the BrdU index of the control D-NAME-treated animals (p  0.017; F 	
124.2). Total cell number in the L-NAME-treated brain was also significantly increased: to 134% of D-NAME-treated control (p 0.017; F	 9). Cell density was also increased
after treatment with ETU: 125% of control D-NAME-treated animals (p  0.017; F 	 40). At the same time there was no significant difference between any of the examined
parameters in D-NAME- or saline-treated animals.
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et al., 2000). The molecular mechanisms by which NO inhibits cell
proliferation are poorly characterized. NO is a highly reactive
molecule, which may interact with and modify a number of
potential targets. In addition to guanylate cyclase and ribonucle-
otide reductase (Garg and Hassid, 1989; Lepoivre et al., 1990;
Kwon et al., 1991; Bredt and Snyder, 1994b; Nathan and Xie,
1994; Wingrove and O’Farrell, 1999), two direct targets of NO,
the genes and proteins that mediate the antiproliferative activity
of NO may include the components of the retinoblastoma (Rb)
pathway such as p21 (Poluha et al., 1997), cell cycle-dependent
kinases (Ishida et al., 1997), or Rb and E2F (Kuzin et al., 2000;
Jaffrey et al., 2001).
NO can affect both the cell in which it is produced and its
neighbors. Indeed, the distribution of NOS-positive neurons rel-
ative to the tectal germinal zone is compatible with NO acting
either in an autocrine or in a paracrine manner. NO may induce
cell cycle arrest in proliferating cells within a zone of its diffusion
after being produced by nearby sources such as the newly differ-
entiated tectal neurons. These data support a model of brain
morphogenesis in which the transcellular messenger NO coordi-
nates the switch from proliferation to differentiation within
groups of cells to create the complex anatomy of the brain.
An increasing number of developmental systems provide evi-
dence that the ability of NO to prevent DNA synthesis and cell
division is exploited as a part of a developmental program in a
variety of tissues. NO synthesis is essential for the transition from
cell proliferation to cell cycle arrest during organ development in
fruit fly (Kuzin et al., 1996; Peunova et al., 1996; Kuzin et al.,
2000), ecdysone-induced neurogenesis in the optic lobe in moth
(Champlin and Truman, 2000), hematopoiesis in mouse (T. Mi-
churina, P. Krasnov, and G. Enikolopov, unpublished results),
and brain development in frog (this study). In addition, NO is
crucial for the differentiation of cultured neuronal cells (Peunova
and Enikolopov, 1995; Obregon et al., 1997; Poluha et al., 1997;
Cote et al., 1998; Phung et al., 1999; Nakagawa et al., 2000),
endothelial cells (Papapetroupoulos et al., 1997a,b; Babaei et al.,
1998), adipocytes (Nisoli et al., 1998), osteoblasts (Hikiji et al.,
1997), myoblasts (K. H. Lee et al., 1997; Kim et al., 1998), and
cardiomyocytes (Bloch et al., 1999).
NO may also be important for the control of cell division in the
developing and adult mammalian brain. However, the effects of
NO on neurogenesis have not yet been established using NOS
mutant mice. In addition, attempts to probe the role of NO in
mammalian brain morphogenesis are complicated by the unusual
complexity of NOS genes: in particular, the use of alternative
promoters and splice sites leads to the generation of multiple
nNOS RNA and protein isoforms (Brenman et al., 1997; Eliasson
et al., 1997; M. A. Lee et al., 1997; Wang et al., 1999), and some
of these isoforms may compensate for the genetic defects in
nNOS mutants (Huang et al., 1993; Brenman et al., 1996). It will
be important to examine the role of NO in mammalian brain
development by performing rigorous quantitative analysis of neu-
rogenesis in NOS-null mutant mice.
Interestingly, we have observed a transient elevation of NOS
expression in various tissues and organs of the developing Xeno-
pus tadpole in addition to the brain (Peunova, unpublished ob-
servations). Blood vessels, muscles, skin, heart, and kidney of
developing Xenopus express NOS during organogenesis, suggest-
ing that NO may play an antiproliferative role during develop-
ment of these tissues as well. Indeed, NOS levels are transiently
increased during the development of many tissues and organs in
mammals, where this transient elevation often coincides with the
cessation of division of committed precursor cells (Bredt and
Snyder, 1994a; Blottner et al., 1995; Collin-Osdoby et al., 1995;
Shaul, 1995; Wetts et al., 1995). In addition, NOS activity is
greatly elevated in regenerating tissues (Collin-Osdoby et al.,
1995; Hortelano et al., 1995; Bruch-Gerharz et al., 1998; Poppa et
al., 1998). Together, studies of various tissues and cell types,
including the brain, suggest that NO may regulate morphogenesis
by acting as an endogenous negative regulator of cell
proliferation.
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